S ince 2014, the new period of all oral direct-acting antivirals (DAA) for the treatment of chronic hepatitis C (CHC) with higher response rates, shorter course of therapy, and fewer side effects (1) (2) (3) (4) (5) has transformed CHC to a curable disease. The World Health Organization (WHO) has set a target of 80% cured of CHC by 2030 to achieve the goal of hepatitis C virus (HCV) elimination.
S
ince 2014, the new period of all oral direct-acting antivirals (DAA) for the treatment of chronic hepatitis C (CHC) with higher response rates, shorter course of therapy, and fewer side effects (1) (2) (3) (4) (5) has transformed CHC to a curable disease. The World Health Organization (WHO) has set a target of 80% cured of CHC by 2030 to achieve the goal of hepatitis C virus (HCV) elimination. (6) Twenty-eight countries have set targets for HCV elimination and developed national plans to access effective prevention, diagnosis, and treatment services, (7) and nine countries are on course to eliminate HCV by 2030. (8) WHO reported that by 2015, 7% of an estimated 71 million persons living with CHC worldwide have accessed HCV treatment. (9) Achieving HCV elimination requires increasing access to HCV treatment among all populations, including those who live in low-and middle-income countries; innovative methods of scale-up include mass screening, producing generic DAA, lifting restrictions on fibrosis scores and drug and alcohol screens, and other pharmaceutical-government partnerships. (8, (10) (11) (12) In the United States, the National Viral Hepatitis Action Plan has set the goal of curing 90%, or 3.15 million, of those with CHC by 2030 and estimates, as of 2014, that HCV treatment has occurred in only 9%. (13) The Veterans Health Administration (VHA) exemplifies how to broaden access, with over 92,000 HCV-infected veterans having been treated. VHA has developed an infrastructure to support treatment and obtain access to HCV therapies for all veterans (14) and is on track to eliminate HCV among veterans who are willing and able to be treated. (15) Although scale-up of HCV treatment is occurring in a few health care systems, (16, 17) there remain gaps in our knowledge about the impact of HCV screening programs, insurance restrictions, and comorbidities on access to HCV treatment. The degree of access to HCV treatment in non-VHA health care settings is unknown.
Access to HCV treatment is especially important in those populations in whom CHC is highly prevalent, such as those with mental health or substance use disorders (MH/SUD). (18) The prevalence of HCV infection among those with mental disorders is estimated to be 17.4% (95% confidence interval [CI], 13.2, 22.6), (19) and the estimated lifetime rate among people who inject drugs (PWID) is 43%. (20) Additionally, treatment of HCV among PWID will lead to a reduction in HCV transmission, (21) which must occur to achieve HCV elimination.
Before DAA, there were disparities in access to treatment among those with MH/SUD (22) due in part to interferon-induced side effects. However, in the DAA period with highly efficacious drugs, these disparities should be changing. As HCV treatments have fewer side effects and contraindications, treatment is occurring in different populations, as evidenced by a study in British Columbia that compared interferon-with DAA-based treatment from 2000 to 2015. They found that those with human immunodeficiency virus (HIV ) infection, cirrhosis, decompensated cirrhosis, diabetes, a history of injection drug use, and opioid substitution treatment were more likely to receive DAA-based compared with interferon-based therapy. (23) Other real-world studies, such as the TRIO study, composed of an extensive network of academic and community practices, reported that among those prescribed HCV treatment, those without cirrhosis or treatment experience were less likely to receive HCV drugs compared with those with cirrhosis or treatment naïve. (24) However, these data provide information on those who were evaluated and prescribed HCV treatment, but they do not provide information on those diagnosed with CHC within a health care system who may not have been assessed or referred for HCV treatment. We sought to understand how access and predictors to treatment have changed in the pre-DAA and post-DAA period in four health care settings using an outpatient-based population aRtiCle iNFoRMatioN: strategy to include those who may not have been evaluated by a specialty clinic. We a priori hypothesized that we would observe an increase in access to HCV treatment, among MH/SUD populations who have traditionally had less access, in the post-DAA period compared with the pre-DAA period.
Materials and Methods

StUDy popUlatioN, CliNiCal SettiNg, aND payeR ReStRiCtioNS
This study included all adults diagnosed with CHC who had an outpatient encounter in one of four urban health care settings from January 1, 2011, to February 28, 2017. Parkland Health & Hospital System (PHHS) in Dallas, Texas, is a large safety-net system and had over 1 million outpatient visits in 2016. In this health care system, pharmaceutical-based patient assistance programs (25) were used to obtain HCV treatment for uninsured patients. Restrictions for insured patients varies. For Texas, Medicaid limits access to those with stage 3 or 4 fibrosis and no evidence of alcohol or active drug use by toxicology screen within 3 months. Prescribers must be specialists or have received a consult with a specialist. Alameda Health System in Oakland, California, is a safety-net system with over 316,000 outpatient visits. In California, the Medicaid program has fewer restrictions on fibrosis, prescriber requirements, and drug and alcohol use. Ochsner Health System, which is a nonprofit, academic health care system in New Orleans, Louisiana, cares for over 600,000 patients annually. The Medicaid program in Louisiana restricts access to those with fibrosis (stage 3 or higher) with no history of drug or alcohol use within 6 months, and limits prescribers to specialists. The Liver Institute of Virginia (LIV ) in Richmond, Virginia, is a private specialty group with over 13,600 outpatient visits. In Virginia, the Medicaid program does not restrict access by fibrosis stage, but does require evaluation for current drug or alcohol use, and prescribers can be specialists or have a consultation with a specialist. In general, Medicare does not impose restrictions by fibrosis stage, drug or alcohol history, or prescriber. However, managed Medicare, as well as commercial plans, have different limits on fibrosis stage of 2 or higher, abstinence requirements from substance use that vary from 1 to 6 months, and prescriber requirements of specialist or consultation with a specialist.
iNClUSioN aND eXClUSioN CRiteRia
At each site, any adult patient (≥18 years of age) included had CHC identified by electronic health record (EHR) using 
Data SoURCeS
Alameda collected data through manual extraction of patient records using a detailed study protocol. At this site, HCV patients were identified using a prospective longitudinal data registry and laboratory data on all HCV antibody positive with positive HCV RNA. A coordinator extracted data manually from EHR using a standard data extraction dictionary used by all sites. A second reviewer validated the data by chart review of a random sample of 10% of charts. All other sites extracted data through their EHR using the Epic system. Specifically, sociodemographic, insurance status, the severity of illness, and other patient characteristics were collected from patient records; outpatient files included the reason for encounter and type of physician, and inpatient files included reason(s) for admission, discharge, comorbidities, and procedures performed. Laboratory data files included all lab visits and results. Pharmacy files included drugs dispensed, duration of treatment, and refills (if prescribed). Prescriptions filled for HCV treatment were coded as HCV treated and were used as a surrogate for access to HCV therapy.
VaRiaBleS oF iNteReSt
In addition to patient demographics, we examined comorbidities, which were coded as yes/no variable based on ICD-9 or ICD-10 diagnosis codes. These comorbidities were selected because these populations either had lower access to HCV treatment in the past (22, 26, 27) or were considered to be a high priority for HCV treatment. 
DeFiNitioN oF MeNtal HealtH aND SUBStaNCe USe DiSoRDeRS
Chart review or EHR abstraction using a broad range of ICD-9 codes (290-319) and ICD-10 codes (F01-F99) were used to code MH/SUD as yes/no if present. To better understand diagnoses encompassed under this broad category of MH/SUD, we performed a subgroup analysis with detailed mental health comorbidities available from two sites (PHHS and LIV) that had in-patient hospital encounter data. The following mental health and substance use diagnoses were examined (see Supporting Table S1 for ICD-9 and ICD-10 codes): anxiety disorder, other psychiatric/mood disorders, manic/bipolar disorder, major depression, schizophrenia/psychosis, alcohol disorder, opioid disorder, cannabis disorder, stimulants, hallucinogens, inhalants, and nicotine disorder.
StatiStiCal appRoaCH
Data on those receiving HCV treatment were presented as proportions and frequencies, and comparison of treatment proportions between groups was made using chi-square testing. Time-dependent analyses of receiving HCV treatment were calculated by KaplanMeier (KM) method with January 1, 2011, as the study initiation. Patients were followed until treatment, death, or end of study, February 2017. KM curves were adjusted for the variables listed below used in the final model. We examined the impact of comorbidities on the cumulative risk of receipt of HCV treatment over time, and we examined those with these comorbidities versus those without. Independent predictors of receiving HCV treatment in the pre-and post-DAA periods were evaluated using multivariate generalized estimating equations (GEE) models that mitigate the effect of clustering given the use of four sites in this study (29) . Because the dependent variable is binary, the binomial distribution was specified in the GEE model with logit link function. Clustering can result in having patients from one location with health or outcomes that are correlated, leading to violation of the independence assumptions made by traditional regression procedures. This violation is particularly relevant to estimates of the variability of estimates. (30) To better understand the impact of MH/SUD, we used a modified Poisson regression model (31, 32) to account for the rare outcomes. We used a binary variance estimator to account for clustering using patient and site combination. We used a sandwich variance estimator to account for both clustering effects and use of the Poisson model as a working model for binary data. (31) In the final models, we selected a priori the following adjustment variables based on what we hypothesized to be important clinical predictors of receiving HCV treatment: age, gender, race/ethnicity, insurance status, and cirrhosis. We calculated the adjusted odds of a patient with HCV during each period of receiving treatment from the study entry date until the end of each period, allowing for a minimum 2-month follow-up. A sensitivity analysis using (1) the above model with only individual identifier as clustering identifier and (2) using GEE model gave similar estimates.
Results
CUMUlatiVe RiSK FoR ReCeiViNg HCV tReatMeNt 2011-2017
Overall, of 29,544 patients with CHC, the cumulative risk of receiving HCV treatment was 16.9% from 2011 through the early part of 2017. In our cohort, 59% had an MH/SUD diagnosis, and among those, the cumulative risk of HCV treatment was 13.6% ( Fig. 1) .
DiFFeReNCeS iN BaSeliNe CHaRaCteRiStiCS By HCV tReatMeNt
Treatment for HCV occurred in only 3.5% of the 16,304 patients with CHC in the pre-DAA period. Those who were aged 45-65 years represented three fourths of the cohort and 83% of those treated. NonHispanic whites were slightly more than half of the cohort, and treatment occurred in 61% of them. Those with commercial or Medicare represented less than half (41%) of the cohort, but 81% of those treated. Additionally, treated patients had a higher proportion of HCC and/or cirrhosis or were post-liver transplant compared with untreated patients (Table 1) . A higher proportion of those not treated in the pre-DAA period were black, had Medicaid or indigent care, and had an MH/SUD. MH/SUD patients represent nearly two thirds of all patients (62%), but only 39% of those treated.
We conducted a secondary analysis to determine the proportion of patients with CHC identified in the pre-DAA period but treated across the entire study period. Out of 16,304 patients with HCV identified in the pre-DAA period, treatment occurred in 2,365 (14.5%) in the whole study period; 574 (24.3% of all those treated) occurred in the pre-DAA before January 1, 2014, and 1,791 (75.7 % of all those treated) occurred in the post-DAA period.
Among the 13,240 with prevalent CHC who entered our study from January 1, 2014, to February 28, 2017 , in the post-DAA period, there was a dramatic increase in the proportion treated, with 1 out 
DiFFeReNCeS iN MeNtal HealtH oR SUBStaNCe USe DiSoRDeRS By HCV tReatMeNt
In a subgroup analysis of the pre-DAA period (Table 2) , among the 9,335 with CHC and an MH/ SUD in our two health systems, 2.4% were treated. A higher proportion of those not treated had major depression, other mood disorders, alcohol use disorder, opioid use disorder, and cocaine use disorder. No one with bipolar/manic disorders or schizophrenia/psychosis received treatment in the pre-DAA period.
Among the 4,283 patients with CHC and an MH/SUD in the post-DAA period, 13.3% were treated. Despite this increase, we found a higher proportion of those untreated had anxiety disorder, other mood disorders, bipolar/manic disorders, and SUD (alcohol, opioid, cannabis, cocaine, stimulants, and nicotine). Notably, there was no difference in the proportion treated versus not treated for major depression.
pReDiCtoRS oF HCV tReatMeNt pRe-Daa aND poSt-Daa
In the pre-DAA period (Fig. 2) , after adjusting for all the baseline variables found in Table 1 
SUBgRoUp aNalySiS pRe-Daa aND poSt-Daa
Patients with CHC and selected MH/SUD were never more likely to be treated across our study period. The specific MH/SUD associated with lower likelihood of treatment changed across the study period. In the pre-DAA period (Fig. 3) , those with alcohol use disorder (AUD) or nicotine use disorder (NUD) were approximately two fifths as likely to be treated compared with those without. Additionally, those with cocaine use disorder (CUD) or stimulant use disorder were approximately one fifth as likely to be treated compared with those without these disorders. In the post-DAA period, those with anxiety disorder, other mood disorders, and manic/bipolar disorder were one third, one half, and 1/10 as likely to be treated compared with those without these disorders, respectively. Those with AUD or NUD were one half and those with CUD were one third as likely to be treated compared with those without these disorders. Furthermore, those with opioid use disorder were 1/20 as likely to be treated.
Discussion
In this large real-world study comprising data from 2011 to 2017 from four large health care settings, we found that in the post-DAA period only 1 in 5 of those with CHC were being treated. WHO and the U.S. Viral Hepatitis Action Plan have set goals of 80%-90% cured by 2030, which require addressing the disparities in access that we found in this study. Those with MH/SUD were less likely to receive HCV treatment compared with those without these disorders. The odds of being treated for HCV among those with MH/SUD improved from the pre-DAA to post-DAA period but still reflects a significantly lower likelihood of obtaining access to treatment. Disparities in age have changed in the post-DAA period, with those >65 years of age having a similar probability of being treated compared with those <45 years of age. But other disparities, as detailed below, persist or have worsened.
Those with any MH/SUD were less likely to receive HCV treatment, with a cumulative risk of receiving HCV treatment of 13.6% compared with 21.6% among those without these disorders. Current DAA have no contraindication with MH/SUD, and proportion treated should be similar in both groups. However, our data do not show this. Reasons for difference in CHC treatment may be due to restrictions by insurance companies, especially state Medicaid programs, which restrict access to HCV treatment among those with SUD. (33) Other barriers may include obtaining referrals because of provider bias or lack of knowledge that new DAA treatments do not have a negative impact on MH disorders, or failure to follow up by the patient for HCV evaluation visits. Despite the American Association for the Study of Liver Diseases/Infectious Diseases Society of America guidance that explicitly recommends HCV treatment for those with MH/SUD comorbidities, (28) data from our health care settings show that we are not achieving this goal.
In our subgroup analysis, we found no association with major depression, suggesting that treatment among those with major depression occurred in a similar proportion as those without this diagnosis. Specialty clinics report a higher probability of treatment among those with depression and post-traumatic disorder (34) ; however, in our study, those with anxiety disorder, other mood/psychiatric disorder, or manic/bipolar disorder in the post-DAA period had significantly lower odds of receiving HCV treatment. There are two reasons that may explain these differences: (1) Many insurance plans have restricted access to those with SUD, reflecting decreased access in this population. (2) A more significant number treated in post-DAA led to increased power to detect differences between those treated versus not. To achieve the goals of HCV elimination, engaging mental health and primary care providers to encourage increased access to HCV treatment in this population will be needed.
There have been changes in the populations treated, with blacks, who represent 38% of our HCV population, having a trend toward a higher likelihood of being treated compared with non-Hispanic whites in the post-DAA period. This difference may be due to higher response rates among blacks receiving DAAcompared with interferon-based treatment. (35, 36) Of note, our data are from 2011, which was the first year that protease-inhibitor-based treatment became available, but it had to be combined with interferon and was less effective in blacks compared with nonblacks. (37, 38) However, disparities by race still exist, as Hispanic whites were less likely to receive HCV treatment compared with non-Hispanic whites in the post-DAA period. Others have found a lower likelihood of receipt of HCV treatment in both blacks and Hispanics in the post-DAA period. (34) Hispanic whites may have lower access to HCV treatment due to language barriers, insurance status, or knowledge about curative treatment.
Disparities in HCV treatment access by insurance has not changed in the post-DAA era. Those with Medicare (26% of our population), Medicaid (19%), and indigent (28%) were less likely to be treated compared with those with commercial insurance. Others have reported disparities in access to HCV treatment especially concerning Medicaid insurance. (39) Although Medicare restrictions have relaxed over time, many state Medicaid programs restrict access by fibrosis stage, substance use, and provider specialty. (40, 41) In the post-DAA period, we observed a decrease in access among those with Medicaid, and we saw no change in access among those who were indigent. Restrictions must be lifted to allow greater access to treatment in the Medicaid population. Additionally, programs are needed to increase treatment among those who are uninsured, which in our health care systems represented almost 30% of those with CHC.
The diagnosis of cirrhosis occurred in 23.8%, concurrent NAFLD in 3.3%, and post-liver transplant in 2.8% of the entire cohort, yet those with CHC and these concurrent diagnoses were significantly more likely to be treated. The reason for this is due to (1) insurance restrictions, which focus on treatment of those with advanced liver disease, and (2) HCV treatment in these health care systems likely being done by a specialist in hepatology/gastroenterology. Improving disparities in access to achieve 2030 goals will require (1) removing the restriction of treatment to those with advanced liver disease and (2) expansion of HCV treatment to nonspecialists, who may be more likely to care for those with other comorbidities.
Our study is different from others because previous cohort studies included only those patients who were seen in a liver clinic (either given treatment or given a prescription). Our data are different because we include those who may not have even been evaluated in a liver clinic, and as such, our study represents a comprehensive outpatient-based population assessment of access. We found that since the availability of DAA, a 5-fold increase in treatment occurred from the pre-DAA to post-DAA period in the proportion of those with CHC obtaining HCV treatment in our four health care settings. Our findings are similar to those of the VHA system, which has also reported a 5-fold increase in the DAA period compared with the interferon period. (17) However, the cumulative risk for receiving HCV treatment among the entire CHC population is 16.9%. Our cohort includes safety-net health systems, which likely have system-level barriers such as infrastructure, insurance, and an inability to engage the at-risk population. Further research is needed to address these barriers and reduce disparities.
Limitations of this study include retrospective design, use of ICD-9 and 10 codes to identify those with HCV and other comorbid conditions, and lack of data on referrals or appointments completed for HCV evaluation. Implementation of the Affordable Care Act (ACA) occurred during this period, which required coverage for preventive care and screening, allowed those with pre-existing conditions to buy health insurance, and provided subsidies for low-income consumers to purchase health insurance. The ACA led to an expansion of Medicaid in some states such as California, but not in other states such as Texas. How these policy changes impacted coverage, restrictions, and access is unknown and unmeasured. Changes in health care policy during the study period may have affected study outcomes such as access to treatment. Our data in the pre-DAA period had significantly fewer who received treatment compared with the post-DAA; thus, the power to detect differences in the pre-DAA period is lower than in the post-DAA period. Caution should be used to interpret the lack of association seen in the pre-DAA period. Similarly, the subgroup analysis by MH/SUD was limited to two sites, and caution should be used to interpret the data because of the small numbers treated in selected categories. We used inpatient ICD-9 and ICD-10 codes for MH/SUD, and this may not be representative of the larger group, which may include more diverse diagnoses. Approximately 15%-30%, varying by site, identified as having CHC did not have a confirmatory HCV RNA. It is possible that some of those could be misclassified, which would introduce a bias toward the null hypothesis and may have led to an underestimation of access to treatment. However, other reasons for lack of confirmatory HCV RNA testing may be due to resource constraints for reflex testing, lack of access to specialty care, and limited knowledge by providers on confirmatory testing. Additionally, those with CHC may have been treated and obtained SVR or had viral clearance. Given the warehousing that many specialists were doing in anticipation of new treatments, (42) (43) (44) it is likely that a small proportion of those with CHC were already treated and cured. However, given the lack of universal screening in our health systems, it is likely that many undiagnosed CHC infections exist within our population and that the true burden of CHC is underestimated. Our data are based on prescriptions for HCV treatment and not the completion of therapy; however, even obtaining a prescription for treatment indicates having some access to treatment, regardless of the outcome. Lack of access to HCV treatment may not reflect provider unwillingness to treat but may represent system barriers such as insurance restrictions, provider barriers such as failure to refer, and patient barriers such as failure to follow up with HCV evaluation visits. Regardless of what barriers may exist, this study does provide evidence of disparities in access to HCV treatment, specifically in those with MH/SUD.
The strength of this study is a large number of CHC from a variety of healthcare settings in different regions of the country. The data is unique because it represents non-VHA health systems, insured and uninsured, and includes multiple co-morbidities. The data presented in this study reflects real-world HCV treatment access across the US. Disparities in access seen in this study are likely to be seen in many healthcare settings especially safety-net systems. Our study examines access to HCV treatment among those with MH/ SUD when DAA treatments were becoming available either to be used in combination with interferon (pre-DAA) or to be used alone (post-DAA). Our study demonstrates that disparities in access to HCV treatment remain and provides insight into specific populations which may need additional attention.
In conclusion, this study demonstrates that the cumulative risk for HCV treatment is <20% among patients with CHC, and that dramatic scale-up is needed in non-VHA systems if we are to achieve the goal of 90% cured by 2030. Despite dramatic changes in the safety and efficacy of current HCV treatment, disparities in access to HCV treatment exist among Hispanic whites and those with noncommercial insurance or those who are indigent. Among those with mental health disorders, gains in access have occurred; however, overall, those with MH/SUD lack access to HCV treatment, even after controlling for extent of liver disease. The goal of HCV elimination requires a strategy that increases access to those with comorbid illnesses, especially those with mental health and substance use, uninsured or underinsured populations, and all racial/ ethnic minorities. Until we can address these disparities in access, we will not be able to achieve the WHO goal of viral elimination by 2030.
